WO2002028432A2 - Procedes reposant sur l'utilisation de cellules embryonnaires pour la prevention et le traitement de la tumorigenese - Google Patents

Procedes reposant sur l'utilisation de cellules embryonnaires pour la prevention et le traitement de la tumorigenese Download PDF

Info

Publication number
WO2002028432A2
WO2002028432A2 PCT/US2001/030839 US0130839W WO0228432A2 WO 2002028432 A2 WO2002028432 A2 WO 2002028432A2 US 0130839 W US0130839 W US 0130839W WO 0228432 A2 WO0228432 A2 WO 0228432A2
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
premalignant
cell
tumor
chemopreventive
Prior art date
Application number
PCT/US2001/030839
Other languages
English (en)
Other versions
WO2002028432A3 (fr
Inventor
Bruce M. Boman
Original Assignee
Ca*Tx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca*Tx, Inc. filed Critical Ca*Tx, Inc.
Priority to AU2002211359A priority Critical patent/AU2002211359A1/en
Publication of WO2002028432A2 publication Critical patent/WO2002028432A2/fr
Publication of WO2002028432A3 publication Critical patent/WO2002028432A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention provides methods for preventing or treating tumor in a subject (e.g., human or non-human animals).
  • the methods comprise administration of an effective amount of chemopreventive or therapeutic agents that stop or reduce generation of mutant stem cells in vivo, that reverse progression of premalignant stem cells that have at least one genetic mutation, or that eliminate premalignant stem cells and tumor stem cell populations.
  • the chemopreventive or therapeutic agents act on premalignant stem cells and tumor stem cells via intracellular, intercellular and tissue pathways that modulate the rate of premalignant or tumor stem cell proliferation. In some methods, chemopreventive or therapeutic agents act on premalignant stem cells and tumor stem cells via intracellular, intercellular or tissue pathways that modulate the number of premalignant or tumor stem cells in vivo. In some other methods, the chemopreventive or therapeutic agents act on premalignant stem cells and tumor stem cells via pathways involving growth factors, cytokines, and their receptors including those that function via autocrine, paracrine, and endocrine loops which control premalignant or tumor stem cells.
  • the chemopreventive or therapeutic agents act on premalignant stem cells and tumor stem cells via cell-to-cell or cell-to-matrix signaling pathways including epithelial stem cell-epithelial stem cell, epithelial stem cell-to-stromal cell, and stem cell-local extracellular matrix environmental interactions or communications.
  • the chemopreventive or therapeutic agents act on premalignant stem cells and umor stem cells via biological pathways that function during development, which lead to the generation of premalignant or tumor stem cells during the development of a subject.
  • the chemopreventive or therapeutic agents act on premalignant stem cells and tumor stem cells via immunological pathways that control premalignant or tumor stem cells.
  • the scheme also shows stem cells (ST) as the initial cell type for generation of Gi phase cells (ST -> G , which simulates the biologic mechanism by which stem cells at the crypt base generate progeny cells for crypt cell renewal (59).
  • ST and the differentiation pathways are coupled to the cell cycle at the phase (60).
  • pathways for de-differentiation of D cells D- Gi
  • proliferation of non- terminally differentiated cells D - S
  • Cell loss is depicted by exit of AC cells from the system, which simulates biological extrusion of apoptotic cells at the crypt lumen (61).
  • the CPD Model design also includes two feedback loop mechanisms (dashed arrows in Figure 1).
  • the TD cell population regulates two steps, D - S and G ⁇ — » S.
  • the apoptotic (AC) cell population regulates three steps, Gi - D, D ⁇ TD, and TD -» AC.
  • Parameters that were incorporated into the model included initial number of ST cells (ST°) and eleven rate constants that govern the rate of the various cell cycle and differentiation/apoptosis steps.
  • A The biological data from FAP and control crypts.
  • the biological data modified from those of Potten (7), are displayed as the percent of bromodeoxyuridine- labeled cells as a function of cell position along the crypt axis for both healthy unaffected human controls (open circles) and FAP patients (solid diamonds).
  • Comparison of the FAP LI to control LI shows that the FAP proliferative abnormality (resulting from a germline APC mutation) involves a shift in the LI toward the crypt top.
  • the FAP LI as compared to the control LI shows a shift in the S-phase curve peak position from 20% to 31.25% along the crypt axis while a slight decrease was observed in the peak height from 25.58% to 23.65% S-phase cells.
  • This proliferative abnormality does not appear to involve hyperproliferation because the total number of labeled cells in FAP crypts is not significantly increased (i.e. the FAPrcontrol ratio for "area-under-the-curve" is 1.05).
  • Figure 1 a computer model ( Figure 1) is used to study the cellular mechanism that links a cancer predisposing germline mutation to the earliest known tissue change in the development of colorectal cancer (CRC).
  • CRC colorectal cancer
  • Theoretical interpretation of complex processes based on mathematical modeling has several advantages. First, modeling provides a defined and quantitative context in which different outcomes can be evaluated and compared following changes in one or more input parameters. Second, modeling can be used to quantitatively test the validity of proposed mechanisms. Finally, modeling provides a rapid and practical method to conduct "experiments" that cannot, because of system complexity, be accomplished by in vitro or in vivo approaches.
  • the tumorigenic process in one hereditary form of CRC familial adenomatous polyposis (FAP) is an ideal system for a modeling study since both the initiating genetic event and earliest tissue change have been identified.
  • the initiating genetic event in FAP tumors and in most sporadic CRC is a mutation in the adenomatous polyposis coli (APC) gene (2).
  • APC adenomatous polyposis coli
  • the earliest known tissue change resulting from a germline APC mutation is an alteration in the distribution of DNA-synthesizing (S phase) cells in histologically normal-appearing colonic crypts of FAP patients.
  • the labeling index (LI) based on tritium-labeled thymidine and bromodeoxyuridine uptake when compared to control crypts from healthy unaffected individuals, displays a shift upwards, away from the crypt base and towards the crypt top (3-7).
  • the S phase cell distribution (LI) profiles for control and FAP crypts, plotted as S phase cell percent vs. crypt axis position, are displayed in Figure 2 (data of Potten et al
  • the CPD model design simulates the cellular dynamics of the colonic crypt ( Figure 1).
  • the model takes into account: (1) that cell proliferation, differentiation, and apoptosis occur continuously in the crypt (16-18), (2) that as epithelial cells migrate up the crypt column they change in their capacity for cell division and differentiation (19), and (3) that the crypt, even in FAP patients, represents a highly regulated steady-state system whereby a constant number of cells is maintained via a balance between cell generation in the lower part of the crypt and cell loss at the top of the crypt (7).
  • Rate constants for each step in the CPD model (see Figure 1 and accompanying legend) and rate equations for the rate of change of each cell type population as a function of time were written (20). Computation was performed by numerical integration (21,22) using an iteration method described previously for other models (23, 24). CPD Model output was graphically displayed as the percent of S-phase cell population (Y- axis) as a function of cell crypt axis position (X-axis). The biological data sets of Potten et al (7) for LI of control and FAP crypts (Fig 2 A) were used because these data appeared to be based on one of the most valid and thorough studies available.
  • This model of CRC initiation via stem cell overproduction may be generally relevant and also explain the initiation of many other cancer types.
  • CPD modeling provides the basis of yet another hypothesis, namely, that
  • APC normally functions to control the number of stem cells in the colonic crypt. While this regulatory property of APC has not yet been described, indirect biological evidence is consistent with this hypothesis.
  • germline inactivation of Tcf4 transcription factor leads to depletion of epithelial stem cell compartments in the small intestine (34).
  • APC controls stem cell numbers
  • the remaining wild-type APC allele is lost (i.e. the second hit according to Knudson's hypothesis (39))
  • a further increase in the number of stem cells will occur.
  • mutation of both APC alleles is sufficient for the growth of early colorectal adenomas in FAP patients (41). Therefore, a logical mechanism for adenoma development is further clonal expansion of the stem cell population due to a second hit in APC.
  • the "stem cell overproduction” mechanism is also consistent with the stem cell model of tumor growth based on the concept of hierarchical proliferation (46, 47).
  • the hierarchical concept holds that neoplasms have a cell-renewal hierarchy that is similar to normal tissues and tumors contain three types of cells: i) proliferating, self- renewing stem cells, ii) proliferating non-renewing transitional cells, and iii) non- proliferating, differentiated end cells (48).
  • the hierarchical concept also proposes that although the stem cell component of tumors is a small subset within the total cell population, its expansion constitutes growth of tumors.
  • That cancer originates from stem cells is not anew concept (49,50), particularly in relation to the origin of leukemias (51-54) and of teratomas (55,56). Indirect evidence also supports a stem cell origin for solid tumors such as CRC. Since tumorigenesis in the colon is a relatively slow process, short-lived non-stem cell populations within crypts are considered an unlikely origin of CRC (14). Additionally, histological evidence from Min/+ mice indicates that multiple differentiated cell types exist in intestinal adenomas, which suggests a stem cell origin for intestinal tumors (15). The present study provides a mechanism for how stem cells are involved in the origin of CRC.
  • CPD modeling has provided insight into the "enormous complexities" of tumorigenesis and has provided a theoretical foundation to understand carcinogenesis in the colon.
  • Results from CPD Model experiments have also provided a theoretical basis for our "stem cell overproduction" hypothesis in CRC development.
  • Rate Constant Values (k 0 to kw) that gave the best fit for both control and FAP biological data were, respectively: 0.05, 0.03, 0.025,
  • Rate constants represent inverse relative time units.
  • Rate equation sets were solved by numerical integration with Mathematica equation- solving software [Mathematica Wolfram Research, Inc., Version 2.2, License # L2516-9472].

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des compositions reposant sur l'utilisation de cellules embryonnaires pour le traitement et la prévention de la tumorigenèse.
PCT/US2001/030839 2000-10-04 2001-10-02 Procedes reposant sur l'utilisation de cellules embryonnaires pour la prevention et le traitement de la tumorigenese WO2002028432A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002211359A AU2002211359A1 (en) 2000-10-04 2001-10-02 Stem cell-based methods for preventing and treating tumor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23866500P 2000-10-04 2000-10-04
US60/238,665 2000-10-04

Publications (2)

Publication Number Publication Date
WO2002028432A2 true WO2002028432A2 (fr) 2002-04-11
WO2002028432A3 WO2002028432A3 (fr) 2003-09-25

Family

ID=22898827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030839 WO2002028432A2 (fr) 2000-10-04 2001-10-02 Procedes reposant sur l'utilisation de cellules embryonnaires pour la prevention et le traitement de la tumorigenese

Country Status (3)

Country Link
US (1) US20020061289A1 (fr)
AU (1) AU2002211359A1 (fr)
WO (1) WO2002028432A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US20050005164A1 (en) * 2003-06-20 2005-01-06 Bronwyn Syiek Apparatus and method for precluding e-mail distribution
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1945754B1 (fr) * 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions et méthodes pour traiter et diagnostiquer un cancer
WO2008092002A2 (fr) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013103A1 (fr) * 1991-01-16 1992-08-06 The Johns Hopkins University Mutations hereditaires et somatiques du gene apc dans les cancers recto-coliques chez l'homme
WO2001016167A2 (fr) * 1999-09-01 2001-03-08 The Johns Hopkins University INTERACTION DE LA β-CATENINE, TCF-4, ET DE L'APC DANS LA PREVENTION DU CANCER

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013103A1 (fr) * 1991-01-16 1992-08-06 The Johns Hopkins University Mutations hereditaires et somatiques du gene apc dans les cancers recto-coliques chez l'homme
WO2001016167A2 (fr) * 1999-09-01 2001-03-08 The Johns Hopkins University INTERACTION DE LA β-CATENINE, TCF-4, ET DE L'APC DANS LA PREVENTION DU CANCER

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BILBAO ET AL.: "Advances in cancer gene therapy" EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 9, no. 6, 1999, pages 711-736, XP002230326 *
MACKILLOP W J ET AL: "A STEM CELL MODEL OF HUMAN TUMOR GROWTH IMPLICATIONS FOR TUMOR CELL CLONOGENIC ASSAYS" JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 70, no. 1, 1983, pages 9-16, XP009005529 ISSN: 0027-8874 cited in the application *
MOSER A R ET AL: "THE MIN MULTIPLE INTESTINAL NEOPLASIA MUTATION ITS EFFECT ON GUT EPITHELIAL CELL DIFFERENTIATION AND INTERACTION WITH A MODIFIER SYSTEM" JOURNAL OF CELL BIOLOGY, vol. 116, no. 6, 1992, pages 1517-1526, XP009005549 ISSN: 0021-9525 cited in the application *
MOYER J D ET AL: "INDUCTION OF APOPTOSIS AND CELL CYCLE ARREST BY CP-358,774, AN INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 21, 1 November 1997 (1997-11-01), pages 4838-4848, XP001009787 ISSN: 0008-5472 *

Also Published As

Publication number Publication date
US20020061289A1 (en) 2002-05-23
AU2002211359A1 (en) 2002-04-15
WO2002028432A3 (fr) 2003-09-25

Similar Documents

Publication Publication Date Title
Ischenko et al. KRAS drives immune evasion in a genetic model of pancreatic cancer
Tsai et al. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Moolgavkar et al. Multistage carcinogenesis: population-based model for colon cancer
Cox et al. Selenoprotein H is an essential regulator of redox homeostasis that cooperates with p53 in development and tumorigenesis
Durrett et al. Evolution of resistance and progression to disease during clonal expansion of cancer
Karin et al. Biphasic response as a mechanism against mutant takeover in tissue homeostasis circuits
Doughty et al. Differential resurgence and response elimination
US20020061289A1 (en) Stem cell-based methods for preventing and treating tumor
Aktipis et al. Dispersal evolution in neoplasms: the role of disregulated metabolism in the evolution of cell motility
Wang et al. Dynamic targeting in cancer treatment
Zhang et al. Revealing dynamic regulations and the related key proteins of myeloma-initiating cells by integrating experimental data into a systems biological model
Zhang et al. Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data
Szabó et al. Blood vessel tortuosity selects against evolution of aggressive tumor cells in confined tissue environments: A modeling approach
Pan et al. A cancer cell cluster marked by LincRNA MEG3 leads pancreatic ductal adenocarcinoma metastasis
Villalba et al. Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Kühn et al. Computational modeling to quantify the contributions of VEGFR1, VEGFR2, and lateral inhibition in sprouting angiogenesis
Komarova Cancer, aging and the optimal tissue design
Gomez et al. Super-enhancer associated core regulatory circuits mediate susceptibility to retinoic acid in neuroblastoma cells
Song et al. Revealing the roles of glycosphingolipid metabolism pathway in the development of keloid: a conjoint analysis of single-cell and machine learning
Komarova et al. Epithelial tissue architecture protects against cancer
McMahon et al. Chapter 13: CISNET lung models: comparison of model assumptions and model structures
Hesse et al. An integrative mathematical model for timing treatment toxicity and Zeitgeber impact in colorectal cancer cells
Woods et al. Exploring the “two‐hit hypothesis” in NF2: Tests of two‐hit and three‐hit models of vestibular schwannoma development
Afenya et al. Some perspectives on modeling leukemia
Khalili et al. Studying the importance of regulatory T cells in chemoimmunotherapy mathematical modeling and proposing new approaches for developing a mathematical dynamic of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP